GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook
Gilead Sciences (NASDAQ:GILD) reported first-quarter 2026 results highlighted by growth in its base business, a higher full-year revenue outlook, and multiple late-stage pipeline and launch milestones...
Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On Revenue
Product Sales Excluding Veklury Increased 8% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.4 billion
June S&P 500 E-Mini futures (ESM26) are up +0.03%, and June Nasdaq 100 E-Mini futures (NQM26) are down -0.01% this morning as investors await the outcome of diplomatic efforts aimed at ending the Iran...
Barchart Research What to Expect from GILD Earnings GILD Generated May 6, 2026 Current Price $136.30 EPS Estimate $$1.89 Consensus Rating Moderate Buy Average Move 4.38% Gilead's HIV Franchise and Oncology...
Earnings To Watch: Gilead Sciences (GILD) Reports Q1 Results Tomorrow
June S&P 500 E-Mini futures (ESM26) are down -0.12%, and June Nasdaq 100 E-Mini futures (NQM26) are down -0.10% this morning, pointing to a lower open on Wall Street as oil prices surged amid renewed...
